Intellia Therapeutics Q2 2023 Earnings Report $12.18 +0.10 (+0.83%) (As of 12/20/2024 05:45 PM ET) Earnings HistoryForecast Intellia Therapeutics EPS ResultsActual EPS-$1.40Consensus EPS -$1.32Beat/MissMissed by -$0.08One Year Ago EPS-$1.33Intellia Therapeutics Revenue ResultsActual Revenue$13.59 millionExpected Revenue$12.08 millionBeat/MissBeat by +$1.51 millionYoY Revenue Growth-3.10%Intellia Therapeutics Announcement DetailsQuarterQ2 2023Date8/3/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseNTLA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Intellia Therapeutics Earnings HeadlinesWhy Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short SellersDecember 12, 2024 | msn.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 22, 2024 | Crypto 101 Media (Ad)Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient InterestNovember 26, 2024 | markets.businessinsider.comIntellia announces FDA granted RMAT designation to nexiguran ziclumeranNovember 26, 2024 | markets.businessinsider.com2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025November 26, 2024 | msn.comSee More Intellia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intellia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intellia Therapeutics and other key companies, straight to your email. Email Address About Intellia TherapeuticsIntellia Therapeutics (NASDAQ:NTLA), a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.View Intellia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
